Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1923]

Complete remission after induction chemotherapy determines clinical efficacy of...

Prof Kristoffer Hellstrand - University of Gothenburg, Gothenburg, Sweden

Complete remission after induction chemotherapy determines clinical efficacy of relapse-preventive immunotherapy in AML ( Prof Kristoffer Hellstrand - University of Gothenburg, Gothenburg, Sweden )

Weekly wKRd-D in newly diagnosed multiple myeloma achieves unprecedented results

Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA

Weekly wKRd-D in newly diagnosed multiple myeloma achieves unprecedented results ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )

Inotuzumab ozogamicin and chemotherapy with or without blinatumomab in...

Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA

Inotuzumab ozogamicin and chemotherapy with or without blinatumomab in Philadelphia chromosone-negative ALL ( Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA )

Study of quadruple combination for induction resistant myeloma reveals novel...

Dr Yael Cohen - Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

Study of quadruple combination for induction resistant myeloma reveals novel immune checkpoints ( Dr Yael Cohen - Tel Aviv Sourasky Medical Center, Tel Aviv, Israel )

Updates on REGN1979 in R/R B-cell non-Hodgkins lymphoma

Dr Rajat Bannerji - Rutgers Cancer Institute of New Jersey, New Brunswick, USA

Updates on REGN1979 in R/R B-cell non-Hodgkins lymphoma ( Dr Rajat Bannerji - Rutgers Cancer Institute of New Jersey, New Brunswick, USA )

Moxetumomab pasudotox-tdfk in heavily retreated r/r hairy cell leukaemia

Dr Robert Kreitman - National Cancer Institute, Bethesda, USA

Moxetumomab pasudotox-tdfk in heavily retreated r/r hairy cell leukaemia ( Dr Robert Kreitman - National Cancer Institute, Bethesda, USA )

Azacitidine plus nivolumab in older adults with AML or MDS

Prof Annette Hay - Queen's University, Ontario, Canada

Azacitidine plus nivolumab in older adults with AML or MDS ( Prof Annette Hay - Queen's University, Ontario, Canada )

Older patients with non-Hodgkin lymphoma can be treated successfully with CAR T...

Dr Karl Kilgore - Avalere Health, Bowie, USA

Older patients with non-Hodgkin lymphoma can be treated successfully with CAR T-cell therapy ( Dr Karl Kilgore - Avalere Health, Bowie, USA )

Depth of response to daratumumab, lenalidomide, bortezomib, and dexamethasone...

Prof Peter Voorhees - Levine Cancer Institute, Charlotte, USA

Depth of response to daratumumab, lenalidomide, bortezomib, and dexamethasone improves over time in transplant-eligible newly diagnosed multiple myeloma ( Prof Peter Voorhees - Levine Cancer Institute, Charlotte, USA )

CARTITIUDE-1: BCMA-targeted CAR T-cell therapy shows high response rates in...

Prof Deepu Madduri - Mount Sinai, New York, USA

CARTITIUDE-1: BCMA-targeted CAR T-cell therapy shows high response rates in patients with multiple myeloma ( Prof Deepu Madduri - Mount Sinai, New York, USA )

Blinatumomab vs chemotherapy as post-reinduction therapy in HR/IR first relapse...

Dr Patrick Brown - Johns Hopkins University, Baltimore, USA

Blinatumomab vs chemotherapy as post-reinduction therapy in HR/IR first relapse of B-ALL in children and adolescents ( Dr Patrick Brown - Johns Hopkins University, Baltimore, USA )

CANDOR: Triple drug combo delays disease progression in stubborn multiple...

Dr Saad Usmani - Levine Cancer Institute, Charlotte, USA

CANDOR: Triple drug combo delays disease progression in stubborn multiple myeloma ( Dr Saad Usmani - Levine Cancer Institute, Charlotte, USA )

More from ecancer